Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer

Media Release



COPENHAGEN, Denmark; March 28, 2023

(Nasdaq: GMAB) announced today that Martine van Vugt has been appointed to Chief Strategy Officer and promoted to Executive Vice President effective March 29, 2023. Martine will oversee Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. Martine joined Genmab in 2001 and most recently served as Genmab’s Senior Vice President, Corporate Strategy & Planning. She will continue her role as a member of the Executive Committee with Genmab’s President and Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, Chief Medical Officer Dr. Tahi Ahmadi, Chief Operating Officer Anthony Mancini, Chief Legal Officer Birgitte Stephensen, and Chief People Officer Chris Cozic.

Based in Genmab’s Global R&D Center in Utrecht, the Netherlands, Martine began her career in scientific and research positions and gained increased responsibility through her time at Genmab leading to extensive experience as participant in many of Genmab’s governance fora. She is a critical contributor to multiple business development strategic collaborations and has been instrumental in the structure and negotiations of key partnerships, among them Genmab’s collaborations with Janssen, BioNTech, and AbbVie.

“Genmab is on an exciting and pivotal journey as we deliver on our promise to bring truly innovative antibody medicines to patients. Martine’s skilled approach to corporate strategy and business development has contributed to productive relationships with our partners and to the successful management of our alliances,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “I’m delighted to recognize Martine for her strong contributions to Genmab.”

Martine has a Ph.D. in Immunology from Utrecht University and a Master of Science degree in Biology from Wageningen University.

About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit and follow us on .

Contact:        

Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: ; E:

Andrew Carlsen, Vice President, Head of Investor Relations

T: ; E:

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; DuoBody in combination with the DuoBody logo^®; HexaBody^®; HexaBody in combination with the HexaBody logo^®; DuoHexaBody^® and HexElect^®.

Media Release no. 03

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment